Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 668 matching drugs for FLT3 — including drugs targeting any of its 13 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
sunitinib FLT3 Direct yes 5
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel FLT3 Direct 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib FLT3 Direct 2
nintedanib FLT3 Direct 2
nintedanib, pembrolizumab FLT3 Direct 2
sorafenib, administered orally, ct/mri FLT3 Direct 2
atezolizumab, tivozanib FLT3 Direct 1
biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging, sunitinib FLT3 Direct 1
byl719, poziotinib, nintedanib, abemaciclib, durvalumab,tremelimumab FLT3 Direct 1
cisplatin, pemetrexed disodium, sorafenib FLT3 Direct 1
conventional surgery, tandutinib, pharmacological study, tissue samples FLT3 Direct 1
everolimus, sorafenib FLT3 Direct 1
gemcitabine, erlotinib, sorafenib FLT3 Direct 1
gemcitabine, placebo, sorafenib FLT3 Direct 1
gemcitabine, sorafenib, radiotherapy FLT3 Direct 1
gemcitabine, sorafenib, vorinostat, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, rosettesep, depfff FLT3 Direct 1
gemcitabine, sunitinib FLT3 Direct 1
lenalidomide, bevacizumab, sorafenib, temsirolimus, lenalidomide, oxaliplatin, leucovorin, 5-fluorouracil FLT3 Direct 1
oxaliplatin, sorafenib FLT3 Direct 1
pacritinib, sirolimus, tacrolimus, allogenic hematopoietic cell transplant (allohct) FLT3 Direct 1
pexidartinib, durvalumab FLT3 Direct 1
ponatinib FLT3 Direct 1
radiation therapy, temozolomide, sorafenib FLT3 Direct 1
ryz101, everolimus, sunitinib, octreotide, lanreotide FLT3 Direct 1
sorafenib FLT3 Direct yes 1
sorafenib, erlotinb FLT3 Direct 1
sorafenib, rad001 FLT3 Direct 1
sorafenib, radiofrequency ablation (rfa) or surgery, everolimus, lanreotide FLT3 Direct 1
sunitinib, placebo FLT3 Direct 1
sunitinib, radiation FLT3 Direct 1
sunitinib, sunitinib FLT3 Direct 1
tivozanib FLT3 Direct 1
topotecan, sorafenib FLT3 Direct 1
trc 105, sorafenib FLT3 Direct 1
vemurafenib, sorafenib FLT3 Direct 1
brigatinib FLT3 Direct yes 0
fedratinib FLT3 Direct yes 0
fedratinib hydrochloride FLT3 Direct yes 0
gilteritinib FLT3 Direct yes 0
gilteritinib fumarate FLT3 Direct yes 0
midostaurin FLT3 Direct yes 0
pexidartinib FLT3 Direct yes 0
pexidartinib hydrochloride FLT3 Direct yes 0
sorafenib tosylate FLT3 Direct yes 0
sunitinib malate FLT3 Direct yes 0
ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine TYMS SSL via TYMS 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
afatinib ERBB2 SSL via ERBB2 yes 3
capecitabine, cisplatin TYMS SSL via TYMS 3
dec-205/ny-eso-1 fusion protein cdx-1401, laboratory biomarker analysis, pharmacological study, sirolimus MTOR SSL via MTOR 3
gemcitabine TYMS SSL via TYMS 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab TYMS SSL via TYMS 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin TYMS SSL via TYMS 2
ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin TYMS SSL via TYMS 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel TYMS SSL via TYMS 2
alvocidib, paclitaxel CDK9 SSL via CDK9 2
asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan TYMS SSL via TYMS 2
asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine TYMS SSL via TYMS 2
avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 TYMS SSL via TYMS 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment TYMS SSL via TYMS 2
bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis TYMS SSL via TYMS 2
biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging TYMS SSL via TYMS 2
biospecimen collection, computed tomography, pemetrexed TYMS SSL via TYMS 2
capecitabine TYMS SSL via TYMS yes 2
capecitabine, carboplatin, epirubicin hydrochloride TYMS SSL via TYMS 2
capecitabine, docetaxel TYMS SSL via TYMS 2
capecitabine, irinotecan hydrochloride TYMS SSL via TYMS 2
capecitabine, oxaliplatin TYMS SSL via TYMS 2
capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy TYMS SSL via TYMS 2
capecitabine, temozolomide TYMS SSL via TYMS 2
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TYMS SSL via TYMS 2
cetuximab, cisplatin, fluorouracil, conventional surgery TYMS SSL via TYMS 2
chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy TYMS SSL via TYMS 2
cisplatin, fluorouracil, surgical procedure, radiation therapy TYMS SSL via TYMS 2
cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab TYMS SSL via TYMS 2
cixutumumab, everolimus, laboratory biomarker analysis, octreotide acetate, pharmacological study MTOR SSL via MTOR 2
durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel TYMS SSL via TYMS 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 TYMS SSL via TYMS 2
everolimus MTOR SSL via MTOR yes 2
filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy TYMS SSL via TYMS 2
filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy TYMS SSL via TYMS 2
fluorouracil, gemcitabine hydrochloride, leucovorin calcium TYMS SSL via TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study TYMS SSL via TYMS 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study HDAC2 SSL via HDAC2 2
fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study TYMS SSL via TYMS 2
fluorouracil, oxaliplatin, conventional surgery, radiation therapy TYMS SSL via TYMS 2
inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide TYMS SSL via TYMS 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TYMS SSL via TYMS 2
irinotecan, capecitabine TYMS SSL via TYMS 2
laboratory biomarker analysis, oxaliplatin, pralatrexate TYMS SSL via TYMS 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.